FGF23 and secondary hyperparathyroidism: This in turn causes maladaptive endocrine changes such as elevation of fibroblast growth factor 23 (FGF23), suppression of 1-alpha hydroxylation in the kidney and development of secondary hyperparathyroidism in humans and reduce longevity44.